--- title: "C4 Therapeutics (CCCC) news: offering" url: "https://aibio.space/companies/c4-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CCCC offering news: C4 Therapeutics prices stock and warrant offering at $2.47, expects $117.0 million net. C4 Therapeutics, Inc." --- CCCC C4 Therapeutics, Inc. NASDAQ · United States # C4 Therapeutics (CCCC) news CCCC offering news Financings · 2025-12-10 ## [C4 Therapeutics registers $125,000,000 in share sales through TD Cowen](https://aibio.space/news/c4-therapeutics-registers-125-000-000-share-sales-through-td-cowen/) The supplement covers $125,000,000 of a sales agreement that allows up to $200,000,000 in total. TD Securities (USA) LLC can earn up to a 3.0% commission, and the filing gives a November 20, 2025 closing price of $2.38. ## Latest C4 Therapeutics news 1. 2025-10-16 Financings [C4 Therapeutics prices stock and warrant offering at $2.47, expects $117.0 million net](https://aibio.space/news/c4-therapeutics-prices-stock-warrant-offering-2-47-expects-117-0/) Each share or pre-funded warrant comes with two warrant classes, each covering 50,608,500 shares at $2.22. C4 says the net proceeds would extend its cash runway to the end of 2028, and the larger $341.7 million figure assumes every warrant is exercised for cash. 2. 2025-06-18 Listings [C4 Therapeutics holders approve doubling authorized shares to 300,000,000](https://aibio.space/news/c4-therapeutics-holders-approve-doubling-authorized-shares-300-000-000/) Stockholders voted 39,547,136 for and 20,664,896 against the increase, with 95,178 abstentions. The company filed the amendment in Delaware the same day. ## C4 Therapeutics at a glance - **Ticker**: CCCC - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $78.6 million ### Related companies - [AFFYMAX INC](https://aibio.space/companies/affymax/) OTC: AFFY - [Kailera Therapeutics](https://aibio.space/companies/kailera-therapeutics/) NASDAQ: KLRA - [Kodiak Sciences](https://aibio.space/companies/kodiak-sciences/) NASDAQ: KOD - [Iambic Therapeutics](https://aibio.space/companies/iambic-therapeutics/) NASDAQ: IAM - [Aditxt](https://aibio.space/companies/aditxt/) OTC: ADTX - [Foghorn Therapeutics](https://aibio.space/companies/foghorn-therapeutics/) NASDAQ: FHTX - [Syndax Pharmaceuticals](https://aibio.space/companies/syndax-pharmaceuticals/) NASDAQ: SNDX - [Nuvation Bio](https://aibio.space/companies/nuvation-bio/) NYSE: NUVB ### Also on NASDAQ - [National Vision Holdings](https://aibio.space/companies/national-vision/) EYE - [Inovio Pharmaceuticals](https://aibio.space/companies/inovio-pharmaceuticals/) INO - [CNS Pharmaceuticals](https://aibio.space/companies/cns-pharmaceuticals/) CNSP - [Corvus Pharmaceuticals](https://aibio.space/companies/corvus-pharmaceuticals/) CRVS - [Alpha Teknova](https://aibio.space/companies/alpha-teknova/) TKNO - [Metagenomi Therapeutics](https://aibio.space/companies/metagenomi-therapeutics/) MGX ## C4 Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$35.9 million](https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/) | [$35.6 million](https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/) | | Research and development | [$104.2 million](https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/) | [$110.6 million](https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/) | | Net income (loss) | [-$105.0 million](https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/) | [-$105.3 million](https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/) | | Cash from operations | [-$98.7 million](https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/) | [-$65.2 million](https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/) | | Cash and equivalents | [$74.6 million](https://www.sec.gov/Archives/edgar/data/1662579/000162828026055494/) | [$55.5 million](https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $78.6 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about C4 Therapeutics Has C4 Therapeutics raised money recently? Our latest story on this, dated Oct 16, 2025: "C4 Therapeutics prices stock and warrant offering at $2.47, expects $117.0 million net". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/c4-therapeutics-prices-stock-warrant-offering-2-47-expects-117-0/). What is the ticker symbol of C4 Therapeutics? C4 Therapeutics, Inc. trades under the ticker CCCC on NASDAQ. Where is C4 Therapeutics listed? C4 Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of C4 Therapeutics? The SEC Central Index Key (CIK) for C4 Therapeutics, Inc. is 1662579. Its filings are on SEC EDGAR. How many shares does C4 Therapeutics have outstanding? 123,025,136 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is C4 Therapeutics listed under? Our directory records C4 Therapeutics, Inc. under United States. What does C4 Therapeutics do? Our directory classifies C4 Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of C4 Therapeutics? The ISIN recorded for C4 Therapeutics, Inc. is US12529R1077. Does aibio.space cover C4 Therapeutics? aibio.space lists C4 Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is C4 Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What was C4 Therapeutics's revenue last year? $35.9 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is C4 Therapeutics profitable? C4 Therapeutics, Inc. reported a net loss of $105.0 million for the fiscal year ended Dec 31, 2025, and used $98.7 million of cash in operations, per its annual report to the SEC. How much does C4 Therapeutics spend on research and development? $104.2 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does C4 Therapeutics have? $78.6 million in cash at Jun 30, 2026, per its 10-Q. What is the latest C4 Therapeutics (CCCC) stock news? Our latest story on C4 Therapeutics, dated Dec 10, 2025: "C4 Therapeutics registers $125,000,000 in share sales through TD Cowen". The supplement covers $125,000,000 of a sales agreement that allows up to $200,000,000 in total. TD Securities (USA) LLC can earn up to a 3.0% commission, and the filing gives a November 20, 2025 closing price of $2.38. [Source](https://aibio.space/news/c4-therapeutics-registers-125-000-000-share-sales-through-td-cowen/). ## Investor discussion: C4 Therapeutics Members talk about C4 Therapeutics (CCCC). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at C4 Therapeutics, newest first. Each line links the filing it comes from. 1. 2025-12-10 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1662579/000119312525314449/d48684d424b5.htm) 2. 2025-10-16 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1662579/000119312525241586/d12915d424b5.htm) 3. 2025-06-18 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1662579/000162828025032155/cccc-20250618.htm) 4. 2024-11-15 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1662579/000162828024048088/prospectussupplement.htm) 5. 2024-10-31 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1662579/000162828024044613/s-3resale.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CCCC on TradingView](https://www.tradingview.com/symbols/NASDAQ-CCCC/). ## SEC filings and registration - **SEC name**: C4 Therapeutics, Inc. - **CIK**: 1662579 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: CCCC (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 490 ARSENAL WAY, WATERTOWN, MA, 02472 - **Phone**: (617) 231-0700 - **Shares outstanding**: 123,025,136 as of 2026-07-31 (10-Q filed 2026-08-11) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1662579/000162828026063497/cccc-20260925.htm) filed 2026-09-25 - [10-Q](https://www.sec.gov/Archives/edgar/data/1662579/000162828026055494/cccc-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1662579/000162828026055490/cccc-20260811.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1662579/000162828026045194/cccc-20260624.htm) filed 2026-06-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1662579/000162828026042365/cccc-20260611.htm) filed 2026-06-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1662579/000162828026035542/cccc-20260515.htm) filed 2026-05-15 - [10-Q](https://www.sec.gov/Archives/edgar/data/1662579/000162828026033865/cccc-20260331.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1662579/000162828026033861/cccc-20260512.htm) filed 2026-05-12 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001662579), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details C4 Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CCCC, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: C4 Therapeutics, Inc. - **Ticker**: CCCC - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US12529R1077 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CCCC/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/c4-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "C4 Therapeutics (CCCC) news: offering", 2026-10-31, https://aibio.space/companies/c4-therapeutics/